| scholarly article | Q13442814 |
| P2093 | author name string | Westphal H | |
| Yaginuma Y | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian carcinoma | Q18556145 |
| P304 | page(s) | 4196-4199 | |
| P577 | publication date | 1992-08-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines | |
| P478 | volume | 52 |
| Q38797735 | A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin |
| Q41141673 | A new cell line from human undifferentiated carcinoma of the ovary: establishment and characterization |
| Q37219099 | Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells |
| Q36079844 | Analysis of the p53 gene in human choriocarcinoma cell lines |
| Q40474530 | Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma. |
| Q52728031 | CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer. |
| Q36782280 | Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer |
| Q35154556 | Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells |
| Q37107517 | Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells |
| Q54217624 | Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas. |
| Q34183833 | Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax. |
| Q52374153 | Di-copper metallodrugs promote NCI-60 chemotherapy via singlet oxygen and superoxide production with tandem TA/TA and AT/AT oligonucleotide discrimination. |
| Q33906118 | Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer |
| Q40025423 | Differences in radiosensitivity between three HER2 overexpressing cell lines |
| Q39874942 | Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis |
| Q40768444 | Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer |
| Q33615837 | Epigenetic control of autophagy by microRNAs in ovarian cancer |
| Q24797891 | Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies |
| Q36619998 | Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin |
| Q35947321 | Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. |
| Q41909130 | HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis |
| Q36354166 | High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation |
| Q37529964 | Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer |
| Q47157561 | In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell |
| Q34540087 | Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB. |
| Q36117479 | Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics |
| Q24291206 | Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells |
| Q24672792 | Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics |
| Q34812489 | Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53 |
| Q36073708 | Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGFβ. |
| Q64054715 | Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53 |
| Q36980164 | Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation |
| Q24634248 | Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers |
| Q71999873 | Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines |
| Q36292196 | Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals |
| Q64079678 | Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer |
| Q90663400 | Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells |
| Q28547093 | Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas |
| Q47548311 | PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma. |
| Q37132090 | Regulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and Krüppel-like factor 5. |
| Q33554192 | Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity |
| Q37140728 | Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity |
| Q34734032 | Retracted: Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: The Activation of the ASK1-ERK-Sp1 Pathway |
| Q37365307 | Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy |
| Q36545745 | Role of cystathionine beta synthase in lipid metabolism in ovarian cancer |
| Q36309603 | Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. |
| Q37177812 | Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines |
| Q30277635 | T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin |
| Q40700411 | Temperature-sensitive ovarian carcinoma cell line (OvBH-1). |
| Q34541738 | Terpenoids from Zingiber officinale (Ginger) induce apoptosis in endometrial cancer cells through the activation of p53 |
| Q37226262 | The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand |
| Q36494563 | The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. |
| Q38406695 | The nucleoside analog clitocine is a potent and efficacious readthrough agent |
| Q36845824 | Trial watch: DNA vaccines for cancer therapy |
| Q37670137 | Triggering autophagic cell death with a di-manganese(II) developmental therapeutic |
| Q35575285 | Wilms' tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck |
| Q35256323 | Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence |
| Q36357596 | c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation |
| Q41254050 | cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines |
| Q24623684 | p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP) |
| Q40979144 | p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization |
| Q34428159 | p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cells |
| Q34618968 | p53 regulates the minimal promoter of the human topoisomerase IIalpha gene |
| Q33814900 | p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication |
Search more.